KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Operating Leases (2020 - 2026)

AbCellera Biologics filings provide 7 years of Operating Leases readings, the most recent being $134.3 million for Q1 2026.

  • Quarterly Operating Leases rose 112.48% to $134.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $134.3 million through Mar 2026, up 112.48% year-over-year, with the annual reading at $137.4 million for FY2025, 126.2% up from the prior year.
  • Operating Leases hit $134.3 million in Q1 2026 for AbCellera Biologics, down from $137.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $137.4 million in Q4 2025 and bottomed at $32.8 million in Q2 2022.
  • Average Operating Leases over 5 years is $82.4 million, with a median of $75.2 million recorded in 2023.
  • The largest annual shift saw Operating Leases surged 162.58% in 2022 before it dropped 21.5% in 2024.
  • AbCellera Biologics' Operating Leases stood at $82.3 million in 2022, then fell by 5.93% to $77.4 million in 2023, then dropped by 21.5% to $60.7 million in 2024, then surged by 126.2% to $137.4 million in 2025, then dropped by 2.25% to $134.3 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Operating Leases are $134.3 million (Q1 2026), $137.4 million (Q4 2025), and $137.1 million (Q3 2025).